Euroasian Journal of Hepato-Gastroenterology

Register      Login

VOLUME 12 , ISSUE S1 ( July, 2022 ) > List of Articles

REVIEW ARTICLE

Gender Differences in Nonalcoholic Fatty Liver Disease

Aabha Nagral, Manisha Bangar, Sherna Menezes, Shobna Bhatia, Nazish Butt, Jhumur Ghosh, Jayani Harshika Manchanayake, Mamun Al Mahtab, Shivaram Prasad Singh

Keywords : Fibrosis, Gender, Gender difference, Liver cancer, Menopause, Metabolic syndrome, Molecular pathogenesis, Nonalcoholic steatohepatitis, Prevalence, Sex hormones

Citation Information : Nagral A, Bangar M, Menezes S, Bhatia S, Butt N, Ghosh J, Manchanayake JH, Al Mahtab M, Singh SP. Gender Differences in Nonalcoholic Fatty Liver Disease. Euroasian J Hepatogastroenterol 2022; 12 (S1):S19-S25.

DOI: 10.5005/jp-journals-10018-1370

License: CC BY-NC 4.0

Published Online: 10-08-2022

Copyright Statement:  Copyright © 2022; The Author(s).


Abstract

Nonalcoholic fatty liver disease (NAFLD) has currently emerged as the most common liver disorder in both developed and developing countries. It has been observed that NAFLD exhibits sexual dimorphism, and there is limited understanding on the sex differences in adults with NAFLD. Nonalcoholic fatty liver disease shows marked differences in prevalence and severity with regards to gender. There are considerable biological disparities between males and females attributed to differences in the chromosomal makeup and sex hormone levels, distinct from the gender differences resulting from the sociocultural influences that lead to differences in lifestyle, which have a significant impact on the pathogenesis of this complex disorder. A multitude of factors contributes to the gender disparities seen and need to be researched in-depth to better understand the mechanisms behind them and the therapeutic measures that can be taken. In this article, we will review the gender disparities seen in NAFLD, as well as recent studies highlighting certain gender-specific factors contributing to its varying prevalence and severity.


PDF Share
  1. Hardy T, Oakley F, Anstee QM, et al. Nonalcoholic fatty liver disease: pathogenesis and disease spectrum. Annu Rev Pathol 2016;11: 451–496. DOI: 10.1146/annurev-pathol-012615-044224.
  2. Ballestri S, Nascimbeni F, Baldelli E, et al. NAFLD as a sexual dimorphic disease: role of gender and reproductive status in the development and progression of nonalcoholic fatty liver disease and inherent cardiovascular risk. Adv Ther 2017;34(6):1291–1326. DOI: 10.1007/s12325-017-0556-1.
  3. Lonardo A, Nascimbeni F, Maurantonio M, et al. Nonalcoholic fatty liver disease: evolving paradigms. World J Gastroenterol 2017;23(36):6571–6592. DOI: 10.3748/wjg.v23.i36.6571.
  4. Kurt Z, Barrere-Cain R, LaGuardia J, et al. Tissue-specific pathways and networks underlying sexual dimorphism in non-alcoholic fatty liver disease. Biol Sex Differ 2018;9(1):46. DOI: 10.1186/s13293-018-0205-7.
  5. Lonardo A, Nascimbeni F, Ballestri S, et al. Sex differences in nonalcoholic fatty liver disease: state of the art and identification of research gaps. Hepatology 2019;70(4):1457–1469. DOI: 10.1002/hep.30626.
  6. Salvoza NC, Giraudi PJ, Tiribelli C, et al. Sex differences in non-alcoholic fatty liver disease: hints for future management of the disease. Explor Med 2020;1:51–74. DOI: 10.37349/emed.2020. 00005.
  7. Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016;64(1):73–84. DOI: 10.1002/hep.28431.
  8. Chitturi S, Farrell GC, George J. Non-alcoholic steatohepatitis in the Asia-Pacific region: future shock? J Gastroenterol Hepatol 2004;19(4):368–374. DOI: 10.1111/j.1440-1746.2003.03252.x.
  9. Kojima S, Watanabe N, Numata M, et al. Increase in the prevalence of fatty liver in Japan over the past 12 years: analysis of clinical background. J Gastroenterol 2003;38(10):954–961. DOI: 10.1007/s00535-003-1178-8.
  10. Zhou YJ, Li YY, Nie YQ, et al. Prevalence of fatty liver disease and its risk factors in the population of South China. World J Gastroenterol 2007;13(47):6419–6424. DOI: 10.3748/wjg.v13.i47.6419.
  11. Jaruvongvanich V, Sanguankeo A, Riangwiwat T, et al. Testosterone, Sex hormone-binding globulin and nonalcoholic fatty liver disease: a systematic review and meta-analysis. Ann Hepatol 2017;16(3): 382–394. DOI: 10.5604/16652681.1235481.
  12. Butt A, Hamid S, Jafri W, et al. Prevalence and risk factors of NAFLD among native South Asian Pakistani patients with type 2 diabetes and metabolic syndrome. Am J Gastroenterol 2011;106:3131.
  13. Eguchi Y, Hyogo H, Ono M, et al. Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study. J Gastroenterol 2012;47(5):586–595. DOI: 10.1007/s00535- 012-0533-z.
  14. Kalra S, Vithalani M, Gulati G, et al. Study of prevalence of nonalcoholic fatty liver disease (NAFLD) in type 2 diabetes patients in India (SPRINT). J Assoc Physicians India 2013;61(7):448–453. PMID: 24772746.
  15. Alam S, Fahim SM, Chowdhury MAB, et al. Prevalence and risk factors of non-alcoholic fatty liver disease in Bangladesh. JGH Open 2018;2(2):39–46. DOI: 10.1002/jgh3.12044.
  16. Park SH, Jeon WK, Kim SH, et al. Prevalence and risk factors of non-alcoholic fatty liver disease among Korean adults. J Gastroenterol Hepatol 2006;21(1 Pt 1):138–143. DOI: 10.1111/j.1440-1746.2005.04086.x.
  17. Wong VW, Chu WC, Wong GL, et al. Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography. Gut 2012;61(3):409–415. DOI: 10.1136/gutjnl-2011-300342.
  18. Li Z, Xue J, Chen P, et al. Prevalence of nonalcoholic fatty liver disease in mainland of China: a meta-analysis of published studies. J Gastroenterol Hepatol 2014;29(1):42–51. DOI: 10.1111/jgh.12428.
  19. Caballería L, Pera G, Auladell MA, et al. Prevalence and factors associated with the presence of nonalcoholic fatty liver disease in an adult population in Spain. Eur J Gastroenterol Hepatol 2010;22(1):24–32. DOI: 10.1097/MEG.0b013e32832fcdf0.
  20. Palmisano BT, Zhu L, Stafford JM. Role of estrogens in the regulation of liver lipid metabolism. Adv Exp Med Biol 2017;1043:227–256. DOI: 10.1007/978-3-319-70178-3_12.
  21. Grossmann M, Wierman ME, Angus P, et al. Reproductive endocrinology of nonalcoholic fatty liver disease. Endocr Rev 2019;40(2):417. DOI: 10.1210/er.2018-00158.
  22. Varlamov O, Bethea CL, Roberts CT Jr. Sex-specific differences in lipid and glucose metabolism. Front Endocrinol (Lausanne) 2015;5:241. DOI: 10.3389/fendo.2014.00241.
  23. Zhang H, Liu Y, Wang L, et al. Differential effects of estrogen/androgen on the prevention of nonalcoholic fatty liver disease in the male rat. J Lipid Res 2013;54(2):345–357. DOI: 10.1194/jlr.M028969.
  24. Besse-Patin A, Léveillé M, Oropeza D, et al. Estrogen signals through peroxisome proliferator-activated receptor-γ coactivator 1α to reduce oxidative damage associated with diet-induced fatty liver disease. Gastroenterology 2017;152(1):243–256. DOI: 10.1053/j.gastro.2016.09.017.
  25. Quinn MA, Xu X, Ronfani M, et al. Estrogen deficiency promotes hepatic steatosis via a glucocorticoid receptor-dependent mechanism in mice. Cell Rep 2018;22(10):2690–2701. DOI: 10.1016/j.celrep.2018.02.041.
  26. Link JC, Chen X, Arnold AP, et al. Metabolic impact of sex chromosomes. Adipocyte 2013;2(2):74–79. DOI: 10.4161/adip.23320.
  27. Chen X, McClusky R, Chen J, et al. The number of x chromosomes causes sex differences in adiposity in mice. PLoS Genet 2012;8(5):e1002709. DOI: 10.1371/journal.pgen.1002709.
  28. Reue K. Sex differences in obesity: X chromosome dosage as a risk factor for increased food intake, adiposity and co-morbidities. Physiol Behav 2017;176:174–182. DOI: 10.1016/j.physbeh.2017.02.040
  29. Bardsley MZ, Falkner B, Kowal K, et al. Insulin resistance and metabolic syndrome in prepubertal boys with Klinefelter syndrome. Acta Paediatr 2011;100(6):866–870. DOI: 10.1111/j.1651-2227.2011.02161.x.
  30. Sharpton SR, Ajmera V, Loomba R. Emerging role of the gut microbiome in nonalcoholic fatty liver disease: from composition to function. Clin Gastroenterol Hepatol 2019;17(2):296–306. DOI: 10.1016/j.cgh.2018.08.065.
  31. de la Cuesta-Zuluaga J, Kelley ST, Chen Y, et al. Age- and sex-dependent patterns of gut microbial diversity in human adults. mSystems 2019;4(4):e00261–19. DOI: 10.1128/mSystems.00261-19.
  32. Sheng L, Jena PK, Liu HX, et al. Gender differences in bile acids and microbiota in relationship with gender dissimilarity in steatosis induced by diet and FXR inactivation. Sci Rep 2017;7(1):1748. DOI: 10.1038/s41598-017-01576-9.
  33. Rosso C, Mezzabotta L, Gaggini M, et al. Peripheral insulin resistance predicts liver damage in nondiabetic subjects with nonalcoholic fatty liver disease [published correction appears in Hepatology. 2017 Sep;66(3):1011]. Hepatology 2016;63(1):107–116. DOI: 10.1002/hep.28287.
  34. Mauvais-Jarvis F, Clegg DJ, Hevener AL. The role of estrogens in control of energy balance and glucose homeostasis. Endocr Rev 2013;34(3):309–338. DOI: 10.1210/er.2012-1055.
  35. Gupte AA, Pownall HJ, Hamilton DJ. Estrogen: an emerging regulator of insulin action and mitochondrial function. J Diabetes Res 2015;2015:916585. DOI: 10.1155/2015/916585.
  36. Park YM, Pereira RI, Erickson CB, et al. Estradiol-mediated improvements in adipose tissue insulin sensitivity are related to the balance of adipose tissue estrogen receptor α and β in postmenopausal women. PLoS One 2017;12(5):e0176446. DOI: 10.1371/journal.pone.0176446.
  37. Hernandez-Gea V, Friedman SL. Pathogenesis of liver fibrosis. Annu Rev Pathol 2011;6:425–456. DOI: 10.1146/annurev-pathol- 011110-130246
  38. Shimizu I, Mizobuchi Y, Yasuda M, et al. Inhibitory effect of oestradiol on activation of rat hepatic stellate cells in vivo and in vitro. Gut 1999;44:127–136. DOI: 10.1136/gut.44.1.127.
  39. Zhang B, Zhang CG, Ji LH, et al. Estrogen receptor β selective agonist ameliorates liver cirrhosis in rats by inhibiting the activation and proliferation of hepatic stellate cells. J Gastroenterol Hepatol 2018;33:747–755. DOI: 10.1111/jgh.13976.
  40. Yang JD, Abdelmalek MF, Pang H, et al. Gender and menopause impact severity of fibrosis among patients with nonalcoholic steatohepatitis. Hepatology 2014;59(4):1406–1414. DOI: 10.1002/hep.26761.
  41. Machado M, Marques-Vidal P, Cortez-Pinto H. Hepatic histology in obese patients undergoing bariatric surgery. J Hepatol 2006;45(4):600–606. DOI: 10.1016/j.jhep.2006.06.013.
  42. Tobari M, Hashimoto E, Taniai M, et al. Characteristics of non-alcoholic steatohepatitis among lean patients in Japan: not uncommon and not always benign [published correction appears in J Gastroenterol Hepatol. 2020 Mar;35(3):516]. J Gastroenterol Hepatol 2019;34(8):1404–1410. DOI: 10.1111/jgh.14585.
  43. Singh S, Allen AM, Wang Z, et al. Fibrosis progression in nonalcoholic fatty liver vs. nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol 2015;13(4):643-54.e1-9. DOI: 10.1016/j.cgh.2014.04.014.
  44. Yatsuji S, Hashimoto E, Tobari M, et al. Influence of age and gender in Japanese patients with non-alcoholic steatohepatitis. Hepatol Res 2007;37(12):1034–1043. DOI: 10.1111/j.1872-034X.2007.00156.x.
  45. Huang DQ, El-Serag HB, Loomba R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol 2021;18(4):223–238. DOI: 10.1038/s41575-020-00381-6.
  46. Stine JG, Wentworth BJ, Zimmet A, et al. Systematic review with meta-analysis: risk of hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis compared to other liver diseases. Aliment Pharmacol Ther 2018;48(7):696–703. DOI: 10.1111/apt.14937.
  47. Tobari M, Hashimoto E, Taniai M, et al. The characteristics and risk factors of hepatocellular carcinoma in nonalcoholic fatty liver disease without cirrhosis. J Gastroenterol Hepatol 2020;35(5):862–869. DOI: 10.1111/jgh.14867.
  48. Ekstedt M, Hagström H, Nasr P, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 2015;61(5):1547–1554. DOI: 10.1002/hep.27368.
  49. Chen QF, Zhou XD, Sun YJ, et al. Sex-influenced association of non-alcoholic fatty liver disease with colorectal adenomatous and hyperplastic polyps. World J Gastroenterol 2017;23(28):5206–5215. DOI: 10.3748/wjg.v23.i28.5206.
  50. Kwak MS, Yim JY, Yi A, et al. Nonalcoholic fatty liver disease is associated with breast cancer in nonobese women. Dig Liver Dis 2019;51(7):1030–1035. DOI: 10.1016/j.dld.2018.12.024.
  51. Lonardo A, Lugari S, Ballestri S, et al. A round trip from nonalcoholic fatty liver disease to diabetes: molecular targets to the rescue? Acta Diabetol 2019;56(4):385–396. DOI: 10.1007/s00592-018-1266-0.
  52. Dai W, Ye L, Liu A, et al. Prevalence of non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus: a meta-analysis. Medicine (Baltimore) 2017;96(39):e8179. DOI: 10.1097/MD.0000000000008179.
  53. Yi M, Chen RP, Yang R, et al. Increased prevalence and risk of non-alcoholic fatty liver disease in overweight and obese patients with type 2 diabetes in South China. Diabet Med 2017;34(4):505–513. DOI: 10.1111/dme.13174.
  54. Akuta N, Kawamura Y, Arase Y, et al. Hepatocellular carcinoma is the most common liver-related complication in patients with histopathologically-confirmed NAFLD in Japan. BMC Gastroenterol 2018;18(1):165. DOI: 10.1186/s12876-018-0900-1.
  55. Santosa S, Jensen MD. The sexual dimorphism of lipid kinetics in humans. Front Endocrinol (Lausanne) 2015;6:103. DOI: 10.3389/fendo.2015.00103.
  56. Svendsen OL, Hassager C, Christiansen C. Age- and menopause-associated variations in body composition and fat distribution in healthy women as measured by dual-energy X-ray absorptiometry. Metabolism 1995;44(3):369–373. DOI: 10.1016/0026-0495(95) 90168-x.
  57. Palmisano BT, Zhu L, Eckel RH, et al. Sex differences in lipid and lipoprotein etabolism. Mol Metab 2018;15:45–55. DOI: 10.1016/j.molmet.2018.05.008.
  58. Ter Horst KW, Gilijamse PW, de Weijer BA, et al. Sexual dimorphism in hepatic, adipose tissue, and peripheral tissue insulin sensitivity in obese humans. Front Endocrinol (Lausanne) 2015;6:182. DOI: 10.3389/fendo.2015.00182.
  59. Arun J, Clements RH, Lazenby AJ, et al. The prevalence of nonalcoholicsteatohepatitis is greater in morbidly obese men compared to women. Obes Surg 2006;16(10):1351–1358. DOI: 10.1381/096089206778663715.
  60. Lee CJ, Clark JM, Asamoah V, et al. Prevalence and characteristics of individuals without diabetes and hypertension who underwent bariatric surgery: lessons learned about metabolically healthy obese. Surg Obes Relat Dis 2015;11(1):142–146. DOI: 10.1016/j.soard.2014.06.012.
  61. Li Y, Chen Y, Tian X, et al. Comparison of clinical characteristics between obese and non-obese patients with nonalcoholic fatty liver disease (NAFLD). Diabetes Metab Syndr Obes 2021;14:2029–2039. DOI: 10.2147/DMSO.S304634.
  62. Allen AM, Therneau TM, Mara KC, et al. Women with nonalcoholic fatty liver disease lose protection against cardiovascular disease: a longitudinal cohort study. Am J Gastroenterol 2019;114(11):1764–1771. DOI: 10.14309/ajg.0000000000000401.
  63. Gambarin-Gelwan M, Kinkhabwala SV, Schiano TD, et al. Prevalence of nonalcoholic fatty liver disease in women with polycystic ovary syndrome. Clin Gastroenterol Hepatol 2007;5(4):496–501. DOI: 10.1016/j.cgh.2006.10.010.
  64. Rocha ALL, Faria LC, Guimarães TCM, et al. Non-alcoholic fatty liver disease in women with polycystic ovary syndrome: systematic review and meta-analysis. J Endocrinol Invest 2017;40(12):1279–1288. DOI: 10.1007/s40618-017-0708-9.
  65. Doucet E, St-Pierre S, Alméras N, et al. Reduction of visceral adipose tissue during weight loss. Eur J Clin Nutr 2002;56(4):297–304. DOI: 10.1038/sj.ejcn.1601334.
  66. Williams RL, Wood LG, Collins CE, et al. Effectiveness of weight loss interventions–is there a difference between men and women: a systematic review. Obes Rev 2015;16(2):171–186. DOI: 10.1111/obr.12241.
  67. Robertson C, Avenell A, Boachie C, et al. Should weight loss and maintenance programmes be designed differently for men? A systematic review of long-term randomised controlled trials presenting data for men and women: the ROMEO project. Obes Res Clin Pract 2016;10(1):70–84. DOI: 10.1016/j.orcp.2015.04.005.
  68. Wirth KM, Sheka AC, Kizy S, et al. Bariatric surgery is associated with decreased progression of nonalcoholic fatty liver disease to cirrhosis: a retrospective cohort analysis. Ann Surg 2020;272(1):32–39. DOI: 10.1097/SLA.0000000000003871.
  69. Gangale MF, Miele L, Lanzone A, et al. Long-term metformin treatment is able to reduce the prevalence of metabolic syndrome and its hepatic involvement in young hyperinsulinaemic overweight patients with polycystic ovarian syndrome. Clin Endocrinol (Oxf) 2011;75(4):520–527. DOI: 10.1111/j.1365-2265.2011.04093.x.
  70. Venetsanaki V, Polyzos SA. Menopause and non-alcoholic fatty liver disease: a review focusing on therapeutic alcoholic perspectives. Curr Vasc Pharmacol 2019;17(6):546–555. DOI: 10.2174/1570161116666180711121949.
  71. McKenzie J, Fisher BM, Jaap AJ, et al. Effects of HRT on liver enzyme levels in women with type 2 diabetes: a randomized placebo-controlled trial. Clin Endocrinol (Oxf) 2006;65(1):40–44. DOI: 10.1111/j.1365-2265.2006.02543.x.
  72. Florentino G, Cotrim HP, Florentino A, et al. Hormone replacement therapy in menopausal women: risk factor or protection to nonalcoholic fatty liver disease? Ann Hepatol 2012;11(1):147–149. PMID: 22166577.
  73. Florentino GS, Cotrim HP, Vilar CP, et al. Nonalcoholic fatty liver disease in menopausal women. Arq Gastroenterol 2013;50(3):180–185. DOI: 10.1590/S0004-28032013000200032.
  74. Loy VM, Joyce C, Bello S, et al. Gender disparities in liver transplant candidates with nonalcoholic steatohepatitis. Clin Transplant 2018;32(8):e13297. DOI: 10.1111/ctr.13297.
  75. Noureddin M, Vipani A, Bresee C, et al. NASH leading cause of liver transplant in women: updated analysis of indications for liver transplant and ethnic and gender variances. Am J Gastroenterol 2018;113(11):1649–1659. DOI: 10.1038/s41395-018-0088-6.
  76. Neuschwander-Tetri BA, Clark JM, Bass NM, et al. Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology 2010;52(3):913–924. DOI: 10.1002/hep.23784.
  77. Taneja S, Roy A. Nonalcoholic steatohepatitis recurrence after liver transplant. Transl Gastroenterol Hepatol 2020;5:24. DOI: 10.21037/tgh.2019.10.12.
  78. Kappus M, Abdelmalek M. De novo and recurrence of nonalcoholic steatohepatitis after liver transplantation. Clin Liver Dis 2017;21(2): 321–335. DOI: 10.1016/j.cld.2016.12.006.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.